Legumain/pH dual-responsive lytic peptide–paclitaxel conjugate for synergistic cancer therapy

After molecule targeted drug, monoclonal antibody and antibody–drug conjugates (ADCs), peptide–drug conjugates (PDCs) have become the next generation targeted anti-tumor drugs due to its properties of low molecule weight, efficient cell penetration, low immunogenicity, good pharmacokinetic and large...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shanshan, Cai, Yue, Hong, Yulu, Gong, Yubei, Gao, Licheng, Li, Qingyong, Li, Le, Sun, Xuanrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176665/
https://www.ncbi.nlm.nih.gov/pubmed/35638851
http://dx.doi.org/10.1080/10717544.2022.2081380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176665/
https://www.ncbi.nlm.nih.gov/pubmed/35638851
http://dx.doi.org/10.1080/10717544.2022.2081380

Ejemplares similares